Compounds > 2-chloro-4-acetotoluidine
Page last updated: 2024-12-06

2-chloro-4-acetotoluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID27967
CHEMBL ID3334594
SCHEMBL ID916728
MeSH IDM0040500

Synonyms (48)

Synonym
AC-18518
nsc 8372
brn 0638223
ai3-23536
2-chloro-4-acetotoluidine
n-(p-tolyl)-alpha-chloroacetamide
p-methylchloroacetanilide
4-methyl-alpha-chloroacetanilide
BB 0217603
acetamide, 2-chloro-n-(p-tolyl)-
2-chloro-n-(p-tolyl)acetamide
p-toluene chloromethylamide
nsc-8372
2-chloro-4-acetotoluidide
4-methyl-.alpha.-chloroacetanilide
acetamide, 2-chloro-n-(4-methylphenyl)-
16634-82-5
2-chloroaceto-p-toluidide
wln: g1vmr d1
p-acetotoluidide, 2-chloro-
nsc8372
n-(chloroacetyl)-p-toluidine
n-(p-tolyl)-.alpha.-chloroacetamide
wln: gr c1 fmv1
2-chloro-4'-methylacetanilide
STK115001
2-chloro-n-(4-methylphenyl)acetamide
AKOS000265715
2-chloro-p-acetotoluidide
ec 435-170-9
2-chloro-n-p-tolyl-acetamide
F1791-1516
FT-0637388
JS-198C
n-(p-tolyl) chloro-acetamide
SCHEMBL916728
DTXSID9075113
acetamide,2-chloro-n-(4-methylphenyl)-
J-509094
CHEMBL3334594
mfcd00018910
n-(4-methylphenyl)-2-chloroacetamide
2-chloro-n-p-tolylacetamide
Z56862730
EN300-01594
F78813
2-chloro-n~1~-(4-methylphenyl)acetamide
PD138946

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The quail treated with a toxic dose of CAT had an increased level of thiobarbituric acid (TBA) reacting products in the liver, with a concomitant decrease in GSH content."( Effects of 2-chloro-4-acetotoluidine (CAT) toxicity on biochemical and morphological alterations in quail.
Barger, AE; Bickford, AA; Giri, SN, )		0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1160975Inhibition of wild-type Escherichia coli MurF compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160966Inhibition of West Nile virus NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160968Inhibition of Escherichia coli MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160974Inhibition of wild-type Escherichia coli MurE compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160971Inhibition of wild-type Escherichia coli MurB compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160973Inhibition of wild-type Escherichia coli MurD compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160969Inhibition of human MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160972Inhibition of wild-type Escherichia coli MurC compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160970Inhibition of wild-type Escherichia coli MurA compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160965Inhibition of Dengue virus serotype 2 NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160967Inhibition of Bovine thrombin using Boc-Val-Pro-Arg-AMC as substrate compound preincubated at 25 uM for 15 mins by fluorescence assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160976GSH reactivity of the compound assessed as adducts formation by RP-HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's3 (42.86)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.13 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		2.3820ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		2.6630barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		1.9710diarylmethane
2-toluidine
2-toluidine: RN given refers to parent cpd. o-toluidine : An aminotoluene in which the amino substituent is ortho to the methyl group.		1.9610aminotoluenecarcinogenic agent
4-nitroacetanilide
[no description available]		2.110
2-chloroacetanilide
[no description available]		2.110
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		1.9710extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
p-chloro-o-toluidine hydrochloride
p-chloro-o-toluidine hydrochloride: structure in first source		1.9610
benzoylamidoacetonitrile
benzamidoacetonitrile: a powerful competitive inhibitor of papain		2.110
n-phenylacrylamide
N-phenylacrylamide: structure in first source		2.110
diethyl maleate
diethyl maleate : A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.		1.9710ethyl ester;
maleate ester		glutathione depleting agent
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		1.9710cysteiniumfundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9610
Bladder Cancer
[description not available]		01.9610
Cancer of Digestive System
[description not available]		01.9610
Diseases, Occupational
[description not available]		01.9610
Respiratory Tract Neoplasms
New abnormal growth of tissue in the RESPIRATORY SYSTEM.		01.9610
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		01.9610
Digestive System Neoplasms
Tumors or cancer of the DIGESTIVE SYSTEM.		01.9610
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9510